Abstract
With Increasing Retinal Disease Prevalence and Unmet Clinical Needs - Which Drug will be the Next Lucentis?
The global prevalences of AMD (age-related macular degeneration) and diabetic
retinopathy are increasing due to rising numbers of older people worldwide. In
addition, the world is facing a "diabetes epidemic", with rapidly-increasing
numbers of people with diabetes and diabetic retinopathy. A clear market
opportunity exists for pharmacological treatments for diabetic retinopathy,
dry AMD and other retinal disorders. From 2009 to 2024, such treatments could
repeat the commercial success that Lucentis achieved in the treatment of wet
AMD. Our latest pharma report - World AMD and Diabetic Retinopathy
Pharmaceutical Market 2009-2024 - examines prospects for the retinal disorder
market over the next 15 years.
The rapid commercial success of Lucentis in treating wet AMD illustrates the
high rewards for successful novel treatments in the retinal disorders market.
There is a clear market opportunity for other drugs to treat diabetic
retinopathy, a condition for which there are currently no approved
pharmacological treatments. Our analysts believe there are further commercial
opportunities for new treatments for geographic atrophy (advanced dry AMD) and
for wet AMD. There is a need for clear advantages over existing wet AMD
therapies, for improved clinical outcomes and ease of dosing. This report
analyses prospects there.
Comprehensive analysis of the market area
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines
that sector critically, through a comprehensive review of information sources,
both primary and secondary. This report provides detailed sales forecasts,
discussions of pipeline developments and analyses of commercial drivers and
restraints, including a SWOT analysis. There are over 55 tables and figures
and three full interviews with experts in the sector. The result is a
comprehensive market- and industry-centred report, with detailed analyses and
informed opinion to benefit your work.
Why you should buy World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024
You will receive the following benefits when you order our report:
- You will receive sales forecasts for the global retinal disorder market,
AMD market,diabetic retinopathy market and the market for other retinal
disorders, together with sales forecasts for leading brands, from 2009 to 2024
- You will read expert opinion from key-opinion leaders in the retinal
disorders pharmaceutical sector, including full transcripts of interviews not
published elsewhere
- You will gain a comprehensive assessment of strengths, weakness,
opportunities and threats for this sector, including discussion of market
drivers and restraints
- You will receive an examination of the future prospects for Lucentis in
the face of competition from off-label use of Avastin, with supporting market
forecasts
- You will obtain a regional analysis of the AMD and diabetic retinopathy
markets, with sales forecasts
- You will receive in-depth analyses of the pharmaceutical pipelines for
AMD, diabetic retinopathy and other retinal disorders.
| 
View Cart
